MarketCatalyst
← Back to Research
Earnings

Viasat Fiscal Q2 2026 EPS Tops Estimates at -$0.32, but Revenue Misses at $1.18B

Revenue of $1.18B vs. $1.20B expected and adjusted EPS of -$0.32 vs. -$0.42; revenue up 3.4% from a year earlier.

Published Nov 5, 2026 · 4:08 PM ET · 2 min read

Viasat (VSAT) posted mixed fiscal second-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $1.18 billion, up 3.4% from a year earlier, below the $1.20 billion estimate, and adjusted EPS was -$0.32, up 29% from a year earlier, above the -$0.42 estimate.

Shares fell 2.2% in after-hours trading as of 4:06 p.m. ET, to $58.08 from a $59.38 close.

-$0.32
Adjusted EPS, up 29% YoY vs. -$0.42 estimate
$1.18B
Revenue, up 3.4% YoY vs. $1.20B estimate
-2.2%
Shares after hours as of 4:06 p.m. ET

Fiscal Q2 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$0.42-$0.32Beat by 24%
Revenue$1.20B$1.18BMiss by 1.8%
ChangeYoYQoQ
Adjusted EPS▲ 29%▲ 16%
Revenue▲ 3.4%▲ 2.0%

By our calculation, revenue was $21.8 million below the estimate and adjusted EPS was $0.10 above it. The QoQ column compares with the previous quarter's revenue of $1.16 billion and adjusted EPS of -$0.38. The YoY column compares with $1.14 billion and -$0.45 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 2 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $1.14 billion, $1.16 billion, $1.17 billion, $1.16 billion and $1.18 billion.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$0.44 and revenue of $1.23 billion next quarter, based on 3 analysts.
  • Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 3.4% increase to $1.18 billion.
  • Estimate record. Whether Viasat returns to beating EPS estimates, which it did in 3 of its last 8 reports.
  • Related coverage. See our reports on Sarepta Therapeutics, Pulse Biosciences, Five9 and Paylocity.

Sources: Results are from Viasat's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Viasat's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.

Viasat Fiscal Q2 2026 EPS Tops Estimates at -$0.32